Stryker Corporation

NYSE:SYK Stock Report

Market Cap: US$125.2b

Stryker Valuation

Is SYK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of SYK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: SYK ($326.54) is trading below our estimate of future cash flow value ($399.79)

Significantly Below Future Cash Flow Value: SYK is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYK?

Key metric: As SYK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SYK. This is calculated by dividing SYK's market cap by their current earnings.
What is SYK's PE Ratio?
PE Ratio37.5x
EarningsUS$3.34b
Market CapUS$125.18b

Price to Earnings Ratio vs Peers

How does SYK's PE Ratio compare to its peers?

The above table shows the PE ratio for SYK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.6x
MDT Medtronic
22.2x10.01%US$106.5b
ISRG Intuitive Surgical
50.6x12.63%US$150.9b
ABT Abbott Laboratories
26.6x12.71%US$166.2b
BSX Boston Scientific
18.8x9.91%US$67.1b
SYK Stryker
37.5x16.37%US$125.2b

Price-To-Earnings vs Peers: SYK is expensive based on its Price-To-Earnings Ratio (37.5x) compared to the peer average (29.6x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does SYK's PE Ratio compare vs other companies in the US Medical Equipment Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EMBC Embecta
1.8x-1.95%US$198.75m
LNSR LENSAR
2.6x-68.24%US$77.47m
MBAI Check-Cap
2xn/aUS$8.31m
ADVB Advanced Biomed
1.7xn/aUS$8.24m
SYK 37.5xIndustry Avg. 26.5xNo. of Companies8PE01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SYK is expensive based on its Price-To-Earnings Ratio (37.5x) compared to the US Medical Equipment industry average (26.5x).

Price to Earnings Ratio vs Fair Ratio

What is SYK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.5x
Fair PE Ratio34.3x

Price-To-Earnings vs Fair Ratio: SYK is expensive based on its Price-To-Earnings Ratio (37.5x) compared to the estimated Fair Price-To-Earnings Ratio (34.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SYK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$326.54
US$386.80
+18.45%
10.36%US$465.00US$315.00n/a25
Jun ’27US$299.46
US$389.24
+29.98%
10.73%US$465.00US$315.00n/a25
May ’27US$294.73
US$394.12
+33.72%
9.80%US$465.00US$315.00n/a26
Apr ’27US$329.40
US$425.08
+29.05%
7.67%US$469.00US$316.00n/a26
Mar ’27US$387.46
US$424.90
+9.66%
7.53%US$469.00US$316.00n/a28
Feb ’27US$369.56
US$424.40
+14.84%
7.65%US$469.00US$316.00n/a28
Jan ’27US$351.47
US$428.11
+21.81%
6.92%US$465.00US$316.00n/a27
Dec ’26US$372.32
US$429.31
+15.31%
7.03%US$465.00US$316.00n/a26
Nov ’26US$356.24
US$429.04
+20.44%
7.12%US$465.00US$316.00n/a26
Oct ’26US$364.15
US$429.92
+18.06%
6.85%US$465.00US$316.00n/a26
Sep ’26US$391.41
US$432.27
+10.44%
6.57%US$465.00US$316.00n/a27
Aug ’26US$377.79
US$431.53
+14.22%
6.44%US$465.00US$316.00n/a27
Jul ’26US$396.74
US$421.46
+6.23%
8.66%US$465.00US$306.00US$313.3928
Jun ’26US$382.64
US$420.92
+10.00%
8.71%US$465.00US$306.00US$299.4628
May ’26US$373.99
US$421.86
+12.80%
6.97%US$465.00US$306.00US$294.7328
Apr ’26US$373.30
US$423.76
+13.52%
6.75%US$465.00US$306.00US$329.4028
Mar ’26US$386.19
US$423.54
+9.67%
7.78%US$465.00US$276.00US$387.4628
Feb ’26US$391.29
US$420.49
+7.46%
7.83%US$465.00US$276.00US$369.5628
Jan ’26US$360.05
US$406.60
+12.93%
7.96%US$450.00US$276.00US$351.4728
Dec ’25US$392.15
US$396.81
+1.19%
7.20%US$450.00US$276.00US$372.3228
Nov ’25US$367.15
US$390.78
+6.44%
7.87%US$420.00US$276.00US$356.2428
Oct ’25US$357.27
US$373.13
+4.44%
8.32%US$406.00US$260.00US$364.1528
Sep ’25US$360.42
US$374.04
+3.78%
7.64%US$406.00US$260.00US$391.4127
Aug ’25US$333.17
US$372.86
+11.91%
8.42%US$406.00US$242.00US$377.7927
Jul ’25US$336.50
US$372.94
+10.83%
8.38%US$406.00US$242.00US$396.7426
US$386.8
Fair Value
15.6% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 05:40
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Stryker Corporation is covered by 53 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays